Sunday, March 01, 2009
Newport Beach, Calif. – Hoag Hospital announced encouraging clinical
study results for the instillation of a patient-specific cancer immune
cell therapy as an adjunctive treatment for glioblastoma multiforme (GBM).
The non-randomized, phase 2 study concluded that intralesional therapy
with autologous lymphokine-activated killer (LAK) cells is safe and the
survival sufficiently encouraging to warrant further evaluation in a randomized
phase 2 trial.
GBM is the most common and deadliest of primarybrain tumor?. Currently,
surgery is the standard therapy for patients. Administering external beam
radiation therapy (EBRT) and chemotherapy after surgery is known to improve
survival rates. However, despite therapeutic advances, survival rates
for GBM continue to be very low.
The article, entitled: “Intralesional Lymphokine-Activated Killer
Cells as Adjuvant Therapy for Primary Glioblastoma,” appeared in
a recent issue of the Journal of Immunotherapy. Lead investigators in
the study were Christopher Duma, MD, FACS, neurosurgeon and medical director
of the Hoag Brain Tumor Program at the Hoag Neurosciences Institute and
Robert O. Dillman, MD, FACP, medical oncologist and cancer immunologist,
as well as executive medical and scientific director at the Hoag Family
Cancer Institute. The study was sponsored by Hoag Hospital Foundation.
“There continues to be a high rate of tumor recurrence in patients
with primary glioblastoma despite advances in treatments, such as chemotherapy,
radiation, and knife radiosurgery. A focus on other local therapies and
immunotherapies that might improve the survival rate for patients with
primary GBM is the next step for identifying treatments that may offer
patients potentially higher survival rates,” said Dr. Dillman.
There were 33 GBM patients enrolled in the clinical trial. Each patient
was treated with their own LAK cells, lymphocytes isolated from the peripheral
blood and stimulated in the Hoag Cell Biology Laboratory with the immune
signaling cytokine interleukin-2 (IL-2). At the time of surgery, the cells
were placed into the surgical cavity. All patients had already undergone
initial surgery, radiation therapy and/or chemotherapy for GBM.
The study resulted in median overall survival from diagnosis of 20.5 months.
In recent reports the median survival for patients treated with surgery,
radiation therapy, and temozolomide chemotherapy was 15 months.
The subsequent, recently opened randomized phase II trial compares the
insertion of LAK cell therapy to the insertion of Gliadel® wafters
at the time of a second craniotomy.
About Hoag Family Cancer Institute
Hoag Family Cancer Institute is accredited as a “Comprehensive Community
Cancer Program” by the Commission on Cancer of the American College
of Surgeons, and was designated as “Outstanding” following
its most recent survey. The Center provides a broad array of innovative
cancer treatments as well as patient-centered education and support programs.
The Hoag Family Cancer Institute has multidisciplinary treatment programs
available for the following cancer types: Bladder,Brain Cancer,Breast
Cancer, Colon,Gynecologic Cancer (Cervical, Ovarian, Uterine),Head &
Neck Cancer,Hematologic Malignancies, Kidney,Lung Cancer,Melanoma Cancer,
Metastic,Prostate Cancer, Rectal, Sarcoma, Testicular and Thyroid. As
the highest volume provider of cancer care in Orange County,Hoag Family
Cancer Institute manages approximately 3,300 newly diagnosed cancer patients
each year, providing the latest state-of-the-art technology and treatment
options. The center participates in a variety of clinical trials, develops
patient-specific biological treatments in its cell biology laboratory,
and provides a wealth of complementary care programs for patients.
About Hoag Neurosciences Institute (HNI)
Hoag Neurosciences Institute (hoag.org/neurosciences) coordinates clinical
neuroscience specialists, dedicated facilities and the latest technology
to provide individualized patient management under the following programs:Memory
and Cognitive Disorders,Brain Tumors,Stroke,Epilepsy,Pain,Movement Disorders,
and Neurobehavioral Disorders. HNI also houses theMultiple Sclerosis,Voice
andSwallowing, and Sleep Centers and is becoming a regional referral center
for all brain andspinal disorders.